Tailoring medicines to an individual’s genetic profile is now possible. One critical aspect is genetic testing that reduces ...

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations ...

SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective ...

That thought process is what is behind the new GeneSight Test from Dr. Brown. It analyzes how a patient’s genes may influence how they metabolize or respond to certain mental health medications.

Myriad Genetics, Inc. More than half say genetic testing for mental health medications could reduce concerns. SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89% ...

The majority of these patients (54%) agree that genetic testing for mental health medications (known as pharmacogenomic or PGx testing) could reduce these concerns.

The GeneSight Psychotropic Test from Myriad Genetics is the category-leading pharmacogenomic (PGx) test for more than 60 medications commonly prescribed for depression, anxiety, ADHD, and other ...

The test, which must be ordered by a healthcare provider, classifies mental health medications into three categories: use as directed, moderate gene-drug interactions and significant gene-drug ...

Juvenile offenders in Porter County soon could have the chance to get genetic testing to see what psychiatric medications might work best for them. The county's juvenile court is partnering with ...

SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective ...